A rare case of pemphigus vulgaris in pregnancy
Challenge in management
DOI:
https://doi.org/10.66344/jpad.v32i1.1823Abstract
Pemphigus vulgaris (PV) is an autoimmune bullous disease manifested as flaccid blisters and extensive erosions of the skin and mucous membranes. Pemphigus vulgaris before or during pregnancy is uncommon, with only 36 cases were reported in current English literature between 1966 and 2014. Management of PV includes immunosuppressive, intravenous immunoglobulins, or biologic agents. Currently, there is no published guideline in the treatment of PV in pregnancy. A 22-year-old pregnant woman at 13 weeks of gestation presented with skin erosions and blisters that worsen for 2 months before hospital admission. Dermatological examination revealed painful erosions and blisters with positive Nikolsky signs on the entire body and numerous oral ulcers accompanied by dysphagia and difficulties in eating. Histopathological examination showed suprabasal clefts filled with acantholytic cells extending to hair follicle units consistent with pemphigus vulgaris. She had been managed with systemic corticosteroid under obstetrician supervision, antibiotic, and supportive care. Her condition was significantly improved over the first month of medical treatment. Pemphigus vulgaris in pregnancy is a challenging case due to the course of the disease itself and the complications of long-term use of the therapeutic agents to both maternal and fetal. Without proper treatment, PV may be fatal due to dehydration and secondary bacterial infections. Patients with PV in pregnancy should be monitored intensively with a multidisciplinary approach to obtain a good outcome for the maternal and the baby.
References
1. Kridin K. Pemphigus group: Overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255-70.
2. Porro AM, Seque CA, Ferreira MCC, Enokihara MMSES. Pemphigus vulgaris. An Bras Dermatol. 2019;94(3):264-78.
3. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-94.
4. Aimee SP, John RS. Pemphigus. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editor. Fitzpatrick’s dermatology. 9th edition. New York: McGraw Hill; 2019.p.909-933.
5. Lin L, Zeng X, Chen Q. Pemphigus and pregnancy. Analysis and summary of case reports over 49 years. Saudi Med J. 2015;36(9):1033-8.
6. Kardos M, Levine D, Gürcan HM, Ahmed RA. Pemphigus vulgaris in pregnancy: Analysis of current data on the management and outcomes. Obstet Gynecol Surv. 2009;64(11):739-49.
7. Genovese G, Derlino F, Berti E, Marzano AV. Treatment of autoimmune bullous diseases during pregnancy and lactation: A review focusing on pemphigus and pemphigoid gestationis. Front Pharmacol. 2020;11:583354.
8. Carvalho AA, Santos Neto DAD, Carvalho MADR, Eleutério SJP, Xavier AREO. Neonatal pemphigus in an infant born to a mother with pemphigus vulgaris: A case report. Rev Paul Pediatr. 2019;37(1):130-34.
9. Kushner CJ, Concha JSS, Werth VP. Treatment of autoimmune bullous disorders in pregnancy. Am J Clin Dermatol. 2018;19(3):391-403.
10. Özdemir Ö, Atalay CR, Asgarova V, Ilgin BU. A resistant case of pemphigus gestationis successfully treated with cyclosporine. Interv Med Appl Sci. 2016;8(1):20-22.
11. Lehman JS, Mueller KK, Schraith DF. Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy?. Arch Dermatol. 2008;144(6):783-5.
12. Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111-9.
13. Fainaru O, Mashiach R, Kupferminc M, Shenhav M, Pauzner D, Lessing JB. Pemphigus vulgaris in pregnancy: A case report and review of literature. Hum Reprod. 2000;15:1195-7.
14. Goldberg NS, DeFeo C, Kirshenbaum N. Pemphigus vulgaris and pregnancy: Risk factors and recommendations. J Am Acad Dermatol. 1993;28(5):877-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Irwan Saputra Batubara
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
